John Kirkwood

Has grant

Distinguished Service Professor of Medicine

University of Pittsburgh

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Kirkwood is a Distinguished Service Professor of Medicine at the University of Pittsburgh, USA. His research primarily focuses on immunotherapy for melanoma and advanced solid tumors, as demonstrated in his recent articles regarding adjuvant nivolumab and the role of CMV in treatment outcomes. He has contributed significantly to clinical trials and analyses aimed at improving patient-reported outcomes and survival rates in oncology.

Recent Grants

Grant: Close

Melanoma and Skin Cancer SPORE

Open Date:

Close Date:

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

vanna chiarion sileni

Chief of Melanoma Oncology Unit

ITALY

View details

Anthony Cillo

Assistant Professor

University of Pittsburgh

UNITED STATES

View details

Dario A. A. Vignali

University of Pittsburgh School of Medicine

UNITED STATES

View details

Niharika Mettu

Duke University

UNITED STATES

View details

Tarek Meniawy

University of Western Australia

AUSTRALIA

View details

Nicholas Iannotti

UNITED STATES

View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES

View details

Charles Owens

Research Services Principal Professional

University of Colorado Anschutz Medical Campus

UNITED STATES

View details

Carol Greider

Professor

University of California, Santa Cruz

UNITED STATES

View details

Christoph Hoeller

Associate Professor, Head of Skin Cancer Center

Medical University of Vienna

AUSTRIA

View details

Piotr Rutkowski

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Kirkwood

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (21)

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial

Response to letter to the editor on “Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial”

Surprising role of CMV in shaping outcomes of immunotherapy for melanoma — chronic infection yields favourable survival

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

Immunotherapy in Melanoma: Recent Advances and Future Directions

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy

TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma

Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma

Targeted Long-Read Bisulfite Sequencing Identifies Differences in the TERT Promoter Methylation Profiles between TERT Wild-Type and TERT Mutant Cancer Cells

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease

Collaborators (11)

vanna chiarion sileni

Anthony Cillo

Dario A. A. Vignali

Niharika Mettu

Tarek Meniawy

Nicholas Iannotti

Bartosz Chmielowski

Charles Owens

Carol Greider

Christoph Hoeller

Piotr Rutkowski

Make your next move.

Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial